Greater Cannabis Company (GCAN) Income towards Parent Company (2017 - 2026)
Greater Cannabis Company (GCAN) recorded quarterly Income towards Parent Company of -$33376.0 in Q1 2026, down 109.88% quarter-over-quarter from $337757.0 in Q4 2025, and up 67.76% on a YoY basis from -$19895.6 in Q1 2025.
Greater Cannabis Company (GCAN) Income towards Parent Company (2017 - 2026) Analysis & Trends
Greater Cannabis Company's Income towards Parent Company history runs 10 years deep, the most recent figure standing at -$33376.0 for Q1 2026.
- In Q1 2026, Income towards Parent Company rose 67.76% year-over-year to -$33376.0; the TTM figure through Mar 2026 stood at -$122571.0 (up 48.49% YoY), while the FY2025 annual figure was -$331612.0, down 85.22% from the prior year.
- Income towards Parent Company was -$33376.0 for Q1 2026 at Greater Cannabis Company, down from $337757.0 in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $337757.0 in Q4 2025 to a low of -$390853.0 in Q2 2025.
- Historically, Income towards Parent Company has averaged -$56105.5 across 5 years, with a median of -$46165.0 in 2024.
- Biggest YoY gain for Income towards Parent Company was 879.18% in 2025; the steepest drop was 770.17% in 2025.
- A 5-year view of Income towards Parent Company shows it stood at -$47401.0 in 2022, then gained by 1.14% to -$46861.0 in 2023, then rose by 7.5% to -$43348.0 in 2024, then soared by 879.18% to $337757.0 in 2025, then sank by 109.88% to -$33376.0 in 2026.
- The last three Income towards Parent Company figures came in at -$33376.0 (Q1 2026), $337757.0 (Q4 2025), and -$36099.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn |
| 10 | Greater Cannabis Company | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33,376.00 |
| Dec 31, 2025 | 337,757.00 |
| Sep 30, 2025 | -36,099.00 |
| Jun 30, 2025 | -390,853.00 |
| Mar 31, 2025 | -103,511.00 |
| Dec 31, 2024 | -43,348.00 |
| Sep 30, 2024 | -46,165.00 |
| Jun 30, 2024 | -44,917.00 |
| Mar 31, 2024 | -44,611.00 |
| Dec 31, 2023 | -46,861.00 |
| Sep 30, 2023 | -53,430.00 |
| Jun 30, 2023 | -45,043.00 |
| Mar 31, 2023 | -43,068.00 |
| Dec 31, 2022 | -47,401.00 |
| Sep 30, 2022 | -102,776.00 |
| Jun 30, 2022 | -62,405.00 |
| Mar 31, 2022 | -147,686.00 |
| Dec 31, 2021 | -196,331.00 |
| Sep 30, 2021 | -252,278.00 |
| Jun 30, 2021 | -38,964.00 |